Superiority of Perineoplasty as Concomitant Surgical Procedure During Pelvic Organ Prolapse Repair (SUPPORT)
Superiority of Perineoplasty as Concomitant Surgical Procedure During Pelvic Organ Prolapse Repair; a Comparative Cohort Trial (SUPPORT)
Study Overview
Status
Status
Conditions
Conditions
Detailed Description
Preoperative measurements, performed at baseline:
- Patient characteristics (age, BMI, smoking, obstetric history)
- Physical examination including POP-Q score. The genital hiatus (gh) at rest (as part of the POP-Q) will be used to assess the wideness of the vaginal introitus.
- Pelvic Floor Distress Inventory (PFDI-20) questionnaire and Patient Global Impression of Severity (PGI-S)
- Pelvic Floor Ultrasound 2DStudy measurements;
- Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire (PISQ-ir), Dutch Perineal Support Questionnaire (DPSQ), General Quality of Life (EQ-5D-5L), Medical Consumption Questionnaire (iMCQ) and Productivity Cost Questionnaire (iPCQ)
- Patient and surgeons considerations with respect to level III repair;
Postoperative measurements:
- Regular physical check-up will be at 4-8 weeks after procedure.
- Physical examination including POP-Q score
- Patient Global Impression of Improvement score (PGI-I)
- Pelvic Floor Ultrasound 2D
- iMCQ, iPCQ, EQ-5D-5L questionnaire
Extra follow up:
- Physical check-up 12 & 24 months after surgery:
- Physical examination including POP-Q score
- Pelvic Floor Ultrasound 2D
- PFDI-20, PGI-I, DPSQ, PISQ-ir, iMCQ, iPCQ, EQ-5D-5L questionnaire
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Jan-Paul Roovers, Prof
- Phone Number: +31 20 5669111
- Email: onderzoeksbureauvkc@amsterdamumc.nl
Study Contact Backup
- Name: Esther van Swieten, MD
- Phone Number: + 31 23 2240000
- Email: suppport-studie@amsterdamumc.nl
Study Locations
-
-
-
Haarlem, Netherlands
- Spaarne Gasthuis
-
Hilversum, Netherlands, 1213PA
- Bergman Clinics
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Female patient >18 years of age
- Complaints of pelvic organ prolapse
- Indication for prolapse surgery (level I and/or level II repair)
- Genital hiatus (GH) according to POP-Q staging of ≥4 cm and ≤7 cm
Exclusion Criteria:
- Unable to understand the Dutch language
- Pregnancy at baseline or intendancy to become pregnant during the study period
- Patients with previous surgery for POP (previous mid urethral sling operations for urinary stress incontinence not excluded)
- Unwilling and / or incapable of giving informed consent
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
Operative procedure; standard treatment
Vaginal level I and/or level II repair will be performed as usual (eg anterior and/or posterior colporrhaphy, sacrospinous fixation etc.) without perineoplasty as decided by surgeon and patient.
This procedure is considered as the control group.
|
|
Operative procedure; standard treatment including level III repair
Vaginal level I and/or level II repair will be performed as usual, but now including perineoplasty (level III repair) as decided by surgeon and patient.
The decision of a perineoplasty to vaginal level I and/or level II repair is based on a shared decision made by surgeon together with the patient.
The considerations upon which this decision has been established in a consensus meeting of Dutch urogynecologists and will be collected by a questionnaire, This group is considered as the 'intervention' group.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Surgical success
Time Frame: 12 months
|
composite outcome defined as meeting the 3 following conditions: [1] "much improved" or "improved" in response to the patient global impression of improvement questionnaire, [2] no re-intervention performed in the same compartment within the first 12 months after index surgery, [3] no stage 2 or more POP in the operated compartment.
|
12 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Morbidity
Time Frame: 24 months
|
complications and re-interventions due to complications, pain
|
24 months
|
|
Effectiveness
Time Frame: 24 months
|
disease specific and general quality of life
|
24 months
|
|
Anatomical outcomes
Time Frame: 24 months
|
24 months
|
|
|
Societal costs
Time Frame: 24 months
|
24 months
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- NL82381.018.22
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.